- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Galectin Therapeutics Inc
+ Add to WatchlistGALT:US
3.9700 USD 0.0100 0.25%As of 20:10:00 ET on 06/19/2013.
Snapshot for Galectin Therapeutics Inc (GALT)
| Open: | 3.9900 | Day's Range: | 3.9500 - 4.0490 | Volume: | 24,165 |
|---|---|---|---|---|---|
| Previous Close: | 3.9800 | 52wk Range: | 1.6000 - 5.2200 | 1-Yr Rtn: | +93.66% |
Key Statistics for GALT
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.7700 |
| Est. EPS (USD) (12/2013) | -0.6900 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 64.52 |
| Shares Outstanding (M) | 16.25 |
| 30 Day Average Volume | 46,569 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GALT
Company Profile & Key Executives for GALT
Galectin Therapeutics Inc. is a drug development company. The Company creates new therapies for fibrotic disease and cancer using its carbohydrate technology that targets galectin proteins which are key mediators of biologic and pathologic functions. Gelectin uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates.
| James C CzirrChairman/Co-Founder | Peter G TraberPresident/CEO/Chief Medical Ofcr |
| Harold H ShlevinCOO/Secretary | Eliezer ZomerExec VP:Manufacturing |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GALT News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page